基于超声的乳腺癌淋巴结转移预测列线图模型的构建与验证
本研究纳入268例乳腺癌患者,随机分为训练组187例和验证组81例,整合原发肿瘤超声参数、腋窝淋巴结超声参数及临床病理指标构建列线图模型。多因素分析显示肿瘤最大径、淋巴结皮质髓质面积比、淋巴结收缩期峰值流速和淋巴结阻力指数为独立危险因素,模型训练组和验证组AUC均为0.958,校准曲线一致性良好。
要点
- 肿瘤最大径、淋巴结皮质髓质面积比、淋巴结收缩期峰值流速、淋巴结阻力指数为腋窝淋巴结转移独立危险因素。
- 基于上述因素构建的列线图模型训练组和验证组AUC均为0.958,预测准确性高。
- 决策曲线分析显示风险阈值0.1-0.6范围内模型净获益最大,具有较强临床实用性。
核心结论
- 肿瘤最大径、淋巴结皮质髓质面积比、淋巴结收缩期峰值流速和淋巴结阻力指数是乳腺癌腋窝淋巴结转移的独立危险因素,基于这些因素构建的预测模型在预测乳腺癌淋巴结转移方面具有高准确性和临床实用性,为乳腺癌患者的个体化治疗提供重要指导。
研究设计与样本
- 本研究为预测模型构建与验证研究,纳入2022年3月至2024年12月在福建省南安市医院治疗的268例乳腺癌患者,按7:3比例随机分为训练组187例和验证组81例,超声测量肿瘤最大径、淋巴结皮质髓质面积比、淋巴结血管收缩期峰值流速和淋巴结阻力指数,并收集病理分级、肿瘤类型、肿瘤位置、绝经状态和年龄等临床病理指标,采用单因素和多因素logistic回归分析构建并验证预测模型,Bootstrap法1000次重复进行内部验证。
诊断标准与关键数值
- 多因素logistic回归显示肿瘤最大径OR=1.463(95%CI:1.250-1.712)、淋巴结皮质髓质面积比OR=11.878(95%CI:1.351-104.449)、淋巴结收缩期峰值流速OR=1.165(95%CI:1.066-1.273)、淋巴结阻力指数OR=5.136(95%CI:2.721-9.693)为腋窝淋巴结转移独立危险因素;列线图模型训练组AUC=0.958(95%CI:0.930-0.986),验证组AUC=0.958(95%CI:0.922-0.995);Bootstrap法1000次重复内部验证校准曲线一致,Hosmer-Lemeshow拟合优度检验p>0.05;决策曲线分析显示风险阈值0.1-0.6范围内模型净获益最大。
临床应用与阅片要点
- 作者认为基于肿瘤最大径、淋巴结皮质髓质面积比、淋巴结收缩期峰值流速和淋巴结阻力指数构建的列线图模型可用于预测乳腺癌腋窝淋巴结转移,为个体化治疗提供指导。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: This study aimed to construct a multifactorial predictive model by integrating ultrasound imaging parameters of primary breast tumors and axillary lymph nodes, along with clinical pathological indicators. The goal was to enhance the accuracy of predicting axillary lymph node metastasis and provide a basis for clinical decision-making.
MATERIALS AND METHODS: A total of 268 breast cancer patients treated at Nan'an Hospital in Fujian Province from March 2022 to December 2024 were included in this study. They were randomly divided into training (187 cases) and validation (81 cases) cohorts in a 7:3 ratio. Ultrasound examinations were conducted to measure parameters such as maximum tumor diameter, lymph node cortex-to-medulla area ratio, the peak systolic velocity and lymph node resistive index of lymph node vascular, along with the collection of clinical pathological indicators, including pathological grade, tumor type, tumor location, menopausal status and age. Univariate and multivariate logistic regression analyses were performed to construct and validate a predictive model for breast cancer lymph node metastasis.
RESULTS: The results of the multivariate logistic regression analysis indicated that tumor maximum diameter (OR = 1.463, 95% CI: 1.250-1.712), lymph node cortex-to-medulla area ratio (OR = 11.878, 95% CI: 1.351-104.449), lymph node peak systolic velocity (OR = 1.165, 95% CI: 1.066-1.273) and lymph node resistive index (OR = 5.136, 95% CI: 2.721-9.693) were independent risk factors for breast cancer lymph node metastasis. The nomogram model constructed based on these factors demonstrated good predictive ability in both the training and validation cohorts, with area under the curves of 0.958 (95% CI: 0.930-0.986) and 0.958 (95% CI: 0.922-0.995), respectively. Internal validation using the Bootstrap method with 1000 repetitions showed consistent calibration curves and Hosmer-Lemeshow goodness-of-fit tests (p > 0.05), indicating good agreement between the predicted and observed probabilities of breast cancer lymph node metastasis. Decision curve analysis revealed that within a risk threshold range of 0.1-0.6, the model provided the greatest net benefit, indicating its strong clinical utility.
CONCLUSION: Tumor maximum diameter, lymph node cortex-to-medulla area ratio, lymph node peak systolic velocity and lymph node resistive index are independent risk factors for axillary lymph node metastasis in breast cancer. The predictive model built on these factors demonstrates high accuracy and clinical utility in predicting breast cancer lymph node metastasis, offering important guidance for individualized treatment of breast cancer patients.
引用
- Huang X, Li X, Lyu H, et al. Construction and Validation of a Nomogram Model for Predicting Lymph Node Metastasis in Breast Cancer Based on Ultrasound. Ultrasound Med Biol. 2025. PMID: 40935770. doi:10.1016/j.ultrasmedbio.2025.07.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。